MDElliottMD: home-claude category backfill (parser-claude gap closure)

2026-05-23T10:43:31Z

home-claude category backfill (parser-claude gap closure)

← Older revision		Revision as of 10:43, 23 May 2026
Line 21:		Line 21:
	== References ==		== References ==
	<references />		<references />
			[[Category:Fibrates]]
			[[Category:Lipid-lowering agents]]
			[[Category:PPAR alpha agonists]]

MDElliottMD: parser-claude batch MedTemplate pre-fill, Top 300 #83

2026-05-23T03:42:09Z

parser-claude batch MedTemplate pre-fill, Top 300 #83

New page

{{MedTemplate
| generic = Fenofibrate
| brand = Tricor, Lipofen, Antara, Fenoglide, Lofibra, Triglide, Trilipix (fenofibric acid)
| structure =
| classes = [[:Category:Fibrates|Fibrate]], [[:Category:Lipid-lowering_agents|Lipid-lowering agent]], [[:Category:PPAR_alpha_agonists|PPAR-α agonist]]
| uses = <vote slug="hypertriglyceridemia-use">Severe hypertriglyceridemia (pancreatitis prevention)</vote>, <vote slug="mixed-dyslipidemia-use">Mixed dyslipidemia (statin-adjunct in selected patients)</vote>
| starting_dose = Varies by salt form and brand; e.g., Tricor 145 mg PO daily; reduce to 48 mg in renal impairment
| preparations = Multiple non-bioequivalent fenofibrate and fenofibric acid formulations: 48-200 mg
| fda_max = Formulation-specific (e.g., 145 mg/d Tricor, 200 mg/d Lipofen)
| pill_id =
| routes = Oral
| onset = Triglyceride lowering at 4-8 weeks
| duration = 24 hours
| halflife = ~20 hours (fenofibric acid, the active metabolite)<ref name="tricor-label">FDA Prescribing Information, Tricor (fenofibrate), AbbVie, current revision. https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/021656s029lbl.pdf</ref>
| bioavailability = Increased with food (varies by formulation; the micronized and nanocrystal forms are less food-dependent)<ref name="tricor-label" />
| pregnancy = Limited data; generally avoided unless triglyceride pancreatitis risk is high.{{citation needed}}
| legal = [[USLegal:Prescription only|Rx-only]] in US
| mechanism = <vote slug="fenofibrate-mech-claim">Fenofibrate is a prodrug hydrolyzed to fenofibric acid, a peroxisome proliferator-activated receptor α (PPARα) agonist; PPARα activation upregulates lipoprotein lipase and apolipoprotein A-I/A-II expression and downregulates apolipoprotein C-III, accelerating VLDL clearance and lowering plasma triglycerides 30-50%.</vote> Modest HDL rise; LDL effects mixed. Renally cleared; combination with statin carries elevated myopathy risk (greater for gemfibrozil than fenofibrate, but caution still warranted)<ref name="tricor-label" />.
}}

== References ==
<references />

Fenofibrate - Revision history

MDElliottMD: home-claude category backfill (parser-claude gap closure)

MDElliottMD: parser-claude batch MedTemplate pre-fill, Top 300 #83